Cucurbitacin B, Purified and Characterized From the Rhizome of Corallocarpus epigaeus Exhibits Anti-Melanoma Potential
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cucurbitacin B, Purified and Characterized From the Rhizome of Corallocarpus epigaeus Exhibits Anti-Melanoma Potential
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-08
DOI
10.3389/fonc.2022.903832
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ROS as a novel indicator to predict anticancer drug efficacy
- (2019) Tarek Zaidieh et al. BMC CANCER
- Facile approach for phytosynthesis of gold nanoparticles from Corallocarbus epigaeus rhizome extract and their biological assessment
- (2019) Selvam Kandasamy et al. Materials Research Express
- Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review)
- (2017) Sukant Garg et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
- (2016) Jasmina Paluncic et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Erratum: Corrigendum: DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria
- (2015) Jayesh Antony et al. Scientific Reports
- Structural Optimization and Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin-Like Functionalities as B-Raf Inhibitors
- (2014) Mahmoud S. Ahmed et al. ChemMedChem
- STAT3 Target Genes Relevant to Human Cancers
- (2014) Richard Carpenter et al. Cancers
- Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma
- (2013) Mahmoud S. Ahmed et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
- (2013) T M Becker et al. ONCOGENE
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer
- (2011) C N Sreekanth et al. ONCOGENE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started